163 related articles for article (PubMed ID: 35463354)
1. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
Front Oncol; 2022; 12():835389. PubMed ID: 35463354
[TBL] [Abstract][Full Text] [Related]
2. Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting.
Wainberg ZA; Xie J; Valderrama A; Yin L; Zhang S; Shih CS; Bhagia P; Gu Q; Shitara K; Janjigian YY; Tabernero J
Clin Cancer Res; 2023 Apr; 29(7):1360-1367. PubMed ID: 36652563
[TBL] [Abstract][Full Text] [Related]
3. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
4. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer.
Gogate A; Ranjan S; Kumar A; Bhandari H; Papademetriou E; Kim I; Potluri R
Front Oncol; 2023; 13():1119102. PubMed ID: 37205193
[TBL] [Abstract][Full Text] [Related]
5. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
[TBL] [Abstract][Full Text] [Related]
6. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer.
Gyawali B; D'Andrea E; Franklin JM; Kesselheim AS
EClinicalMedicine; 2021 Feb; 32():100730. PubMed ID: 33681740
[TBL] [Abstract][Full Text] [Related]
7. Association between event-free survival and overall survival after neoadjuvant treatment for non-small cell lung cancer: a systematic review and meta-analysis.
Ostoros G; Hettle R; Georgoulia N; Berktas M; Chander P; Diaz Perez I; Couto AM; Eichinger C; Field P; Morten P
Expert Rev Anticancer Ther; 2023; 23(12):1305-1313. PubMed ID: 37850939
[TBL] [Abstract][Full Text] [Related]
8. Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.
Zhu J; Tao J; Dai Z; Tan Y; Jiang L; Wang Q; Lang J
Front Oncol; 2021; 11():771546. PubMed ID: 35111667
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.
Black CM; Keeping S; Mojebi A; Ramakrishnan K; Chirovsky D; Upadhyay N; Maciel D; Ayers D
Front Oncol; 2022; 12():868490. PubMed ID: 35574411
[TBL] [Abstract][Full Text] [Related]
10. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
11. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Korn EL; Sachs MC; McShane LM
Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
[TBL] [Abstract][Full Text] [Related]
12. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
13. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Cortazar P; Zhang L; Untch M; Mehta K; Costantino JP; Wolmark N; Bonnefoi H; Cameron D; Gianni L; Valagussa P; Swain SM; Prowell T; Loibl S; Wickerham DL; Bogaerts J; Baselga J; Perou C; Blumenthal G; Blohmer J; Mamounas EP; Bergh J; Semiglazov V; Justice R; Eidtmann H; Paik S; Piccart M; Sridhara R; Fasching PA; Slaets L; Tang S; Gerber B; Geyer CE; Pazdur R; Ditsch N; Rastogi P; Eiermann W; von Minckwitz G
Lancet; 2014 Jul; 384(9938):164-72. PubMed ID: 24529560
[TBL] [Abstract][Full Text] [Related]
15. Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Matsuda S; Itonaga I; Tsumura H
Sci Rep; 2020 May; 10(1):8573. PubMed ID: 32444660
[TBL] [Abstract][Full Text] [Related]
16. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
17. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
[No Abstract] [Full Text] [Related]
18. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
Broglio KR; Quintana M; Foster M; Olinger M; McGlothlin A; Berry SM; Boileau JF; Brezden-Masley C; Chia S; Dent S; Gelmon K; Paterson A; Rayson D; Berry DA
JAMA Oncol; 2016 Jun; 2(6):751-60. PubMed ID: 26914222
[TBL] [Abstract][Full Text] [Related]
19. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.
Fan N; Wang Z; Zhou C; Bludau M; Contino G; Zhao Y; Bruns C
EClinicalMedicine; 2021 Dec; 42():101183. PubMed ID: 34805809
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer.
Huang M; O'Shaughnessy J; Zhao J; Haiderali A; Cortes J; Ramsey S; Briggs A; Karantza V; Aktan G; Qi CZ; Gu C; Xie J; Yuan M; Cook J; Untch M; Schmid P; Fasching PA
J Natl Compr Canc Netw; 2020 Aug; 18(8):1096-1104. PubMed ID: 32755985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]